LEADER 01664oam  2200421   450 
001 9910707492803321
005 20161123101558.0
035   $a(CKB)5470000002464596
035   $a(OCoLC)956436504
035   $a(OCoLC)995470000002464596
035   $a(EXLCZ)995470000002464596
100   $a20160810d2010      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aChallenges to FDA's ability to monitor and inspect foreign clinical trials /$fDepartment of Health and Human Services, Office of Inspector General
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2010.
215   $a1 online resource (iv, 43 pages) $cillustrations, color map
300   $aTitle from title screen (viewed Aug 9, 2016).
300   $a"June 2010."
300   $a"OEI-01-08-00510."
320   $aIncludes bibliographical references.
517 3 $aChallenges to Food and Drug Administration's ability to monitor and inspect foreign clinical trials
606   $aClinical trials$xGovernment policy$zUnited States
606   $aBiologicals$xTesting$xGovernment policy$zUnited States
606   $aDrugs$xTesting$xGovernment policy$zUnited States
615  0$aClinical trials$xGovernment policy
615  0$aBiologicals$xTesting$xGovernment policy
615  0$aDrugs$xTesting$xGovernment policy
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910707492803321
996   $aChallenges to FDA's ability to monitor and inspect foreign clinical trials$93299502
997   $aUNINA